Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan raised its price target on Elanco to $30 (from $28) and kept an overweight rating—implying roughly a 25% upside—while several other firms have also lifted targets, leaving the analyst consensus at a "Moderate Buy" with an average target of $28.10.
• Q1 beat: Elanco reported $0.40 EPS vs. $0.34 expected and $1.37B revenue (+14.9% YoY), and raised FY2026 guidance (revenue $5.01–5.085B; adj. EPS $1.03–1.09) with improved margins and tightened leverage goals.
• Despite the beat, management guided Q2 EPS to $0.250–0.285 (slightly below consensus) and the stock dropped about 8.3% to $24 on heavy volume; the company has a market cap of ~$11.9B and a negative P/E of -50.2.

Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & Co. from $28.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 25.03% from the company's previous close.

A number of other research analysts also recently issued reports on the company. Citigroup initiated coverage on Elanco Animal Health in a report on Wednesday, April 15th. They set a "buy" rating and a $30.00 price target on the stock. KeyCorp increased their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Weiss Ratings raised Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, April 27th. UBS Group restated a "buy" rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Piper Sandler upgraded Elanco Animal Health from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $28.10.

Elanco Animal Health Stock Down 8.3%

NYSE:ELAN traded down $2.19 during trading hours on Thursday, reaching $24.00. 8,155,888 shares of the company traded hands, compared to its average volume of 5,021,183. The business's 50-day moving average price is $23.85 and its two-hundred day moving average price is $23.33. The stock has a market capitalization of $11.93 billion, a P/E ratio of -50.20, a P/E/G ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a 1 year low of $11.83 and a 1 year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health will post 1.03 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company's stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company's stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Invesco Ltd. boosted its stake in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company's stock valued at $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Elanco Animal Health during the first quarter valued at approximately $66,390,000. Finally, Artemis Investment Management LLP bought a new position in Elanco Animal Health during the fourth quarter valued at approximately $55,693,000. Institutional investors own 97.48% of the company's stock.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Quarterly beat — Elanco reported Q1 adjusted EPS of $0.40 (vs. $0.34 consensus) and revenue of $1.371B (+15% YoY; 10% organic), with adjusted EBITDA of $334M and improving margins. These results validate the company’s innovation-led growth. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Upgraded full-year targets — Elanco raised FY2026 guidance (revenue to $5.010B–$5.085B, adjusted EBITDA to $975M–$1,005M, adjusted EPS to $1.03–$1.09) and raised its innovation revenue target to $1.2B; management also tightened year-end net leverage goals to ~3.0–3.2x. These lifts are supportive of forward earnings growth. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Regulatory/product momentum — The company announced emergency use authorizations for Negasunt Powder and Tanidil, supporting near-term product revenue and pipeline proof points that investors value. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum
• Neutral Sentiment: Earnings materials available — Full earnings call transcript and the investor presentation/slide deck were released (useful for details on segments, geography and margin drivers). Elanco Q1 2026 Earnings Call Transcript Q1 Results - Earnings Call Presentation
• Negative Sentiment: Q2 guide slightly soft vs. consensus — Elanco guided Q2 EPS to $0.250–$0.285 vs. a consensus near $0.29 (revenues roughly in line). That miss on the midpoint may have trimmed near-term expectations and contributed to profit-taking after the rally. Elanco Animal Health Reports First Quarter 2026 Results

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.